1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL03, NCT00199004
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML_GT60_DD, NCT00180167
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: LAL-Ph-2000, NCT00526305
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: LAL-AR-N-2005, NCT00526409
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL04, NCT00199017
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
|
|
10.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: EORTC-58951, NCT00003728
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: EORTC-06991, NCT00004128, GIMEMA-EORTC-06991
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: COG-AALL0232, NCT00075725, AALL0232
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI
Protocol IDs: SWOG-S0106, S0106, NCT00085709
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: JALSG ALL202-O, NCT00131027
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: AMLCG 99, BMBF 01 GI 02070, NCT00266136
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 4 at diagnosis
Sponsor: NCI
Protocol IDs: COG-AAML0431, AAML0431, NCT00369317
|
|
19.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005143, NCT00338286
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: COG-AALL0434, AALL0434, NCT00408005
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: ALL-BFM-2000, EU-20682, NCT00430118
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: P060504, EudraCT N° : 2006-005163-26, NCT00428558
|
|
23.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0124, NCT00452439
|
|
24.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0521, S0521, NCT00492856
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, NCT00549848
|
